#Sovaldi

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.

Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.

These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.

In early research in cell cultures and mice, scientists found Sovaldi could possibly thwart Zika’s harmful effects on unborn babies.

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

Such generic drugs could save nations huge sums in the coming years.

The two-drug regimen can cure the virus in as little as eight weeks.

Hepatitis C advocate Peter McLoyd transformed his bad times into good ones.

Gilead Sciences’ HCV combo tablet regimen of Sovaldi and velpatasvir can be combined safely with most “boosted” antiretroviral treatment...

The regimen has been well-studied in combination with numerous HIV antiretrovirals (ARVs).

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.